The development of gene therapy for breast cancer using targeted measles virus vectors

• Project/Area Number: 25430152
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Kyushu University
• Principal Investigator: Matsumura Yumiko 九州大学, 生体防御医学研究所, 研究員 (90594911)
• Co-Investigator(Renkei-kenkyūsha): NAKAMURA Takafumi 鳥取大学, 医学学研究科, 准教授 (70432911) ; TANIGUCHI Hiroaki 東京大学, 医科学研究所, 特任准教授 (90563289)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 遺伝子治療 / 癌治療 / 分子標的薬 / 癌幹細胞 / ウイルスベクター

Outline of Final Research Achievements

Breast cancer contains a heterogeneous population of cells with a small percentage that have increased resistance to conventional therapies and are capable of establishing metastasis. We found that the expression of novel two genes identified the breast cancer stem cells in human cell lines. We engineered the new measles-based viral vectors which have several advantages in targeted gene therapy. In this study, we proved the potential antitumor capability of the engineered vaccine strain of the measles virus against human breast cancer.